Claims
- 1. A compound of formula I
- 2. The compound according to claim 1 wherein Q is SO2.
- 3. The compound according to claim 1 wherein R5 is H.
- 4. The compound according to claim 2 wherein R6 is an optionally substituted aryl or heteroaryl group.
- 5. The compound according to 4 wherein R4 is H or CH3 and R5 is H.
- 6. The compound according to claim 5 wherein R6 is an optionally substituted phenyl or heteroaryl group.
- 7. The compound according to claim 6 wherein R7 is H.
- 8. The compound according to claim 7 wherein R1, R2 and R3 are H.
- 9. The compound according to claim 2 selected from the group consisting of:
2-{(E)-1-[1-(phenylsulfonyl)-1H-pyrrol-3-yl]ethylidene}hydrazinecarboximidamide; 2-{(E)-1-[1-(4-methylphenylsulfonyl)-1H-pyrrol-3-yl]ethylidene}hydrazine-carboximidamide; 2-{(E)-1-[1-(2,4-dimethyl-1-(phenylsulfonyl)-1H-pyrrol-3-yl]ethylidene}hydrazine-carboximidamide; 2-{(E)-1-[1-(naphthylsulfonyl)-1H-pyrrol-3-yl]ethylidene}-1-hydrazine-carboximidamide; 2-{(E)-1-{1-(5-chloro-3-methyl-1-benzothiophen-2-yl)sulfonyl]-1H-pyrrol-3-yl}ethylidene)-1-hydrazinecarboximidamide; 2-((E)-1-{1-[(4-aminophenyl)sulfonyl]-1H-pyrrol-3-yl}ethylidene)-1-hydrazine-carboximidamide; 2-((E)-1-{1-[(2-amino-4-methyl-1,3-thiazol-5-yl)sulfonyl]-1H-pyrrol-3-yl)}ethylidene)-1-hydrazinecarboximidamide; 2-[1-[(phenylsulfonyl)-1,5,6,7-tetrahydro-4H-indol-4-ylidene]-1-hydrazinecarboximidamide; 2-[1-(4-biphenylsulfonyl)-1,5,6,7-tetrahydro-4H-indol-4-ylidene]-1-hydrazinecarboximidamide; 2-[1-(4-bromophenylsulfonyl)-1,5,6,7-tetrahydro-4H-indol-4-ylidene]-1-hydrazinecarboximidamide; 2-[1-(5-chloro-2-methoxyphenylsulfonyl)-1,5,6,7-tetrahydro-4H-indol-4-ylidene]-1-hydrazinecarboximidamide; the stereoisomers thereof; and the pharmaceutically acceptable salts thereof.
- 10. A method for the treatment of a disorder of the central nervous system related to or affected by the 5-HT6 receptor in a patient in need thereof which comprises providing to said patient a therapeutically effective amount of a compound of formula I
- 11. The method according to claim 10 wherein said disorder is a motor disorder, anxiety disorder or cognitive disorder.
- 12. The method according to claim 10 wherein said disorder is schizophrenia or depression.
- 13. The method according to claim 11 wherein said disorder is selected from the group consisting of: Alzheimer's disease; Parkinson's disease; attention deficit disorder; and obsessive compulsive disorder.
- 14. The method according to claim 11 having a formula I compound wherein Q is SO2; R4 is H or CH3; R5 is H; and R6 is an optionally substituted phenyl or heteroaryl group.
- 15. A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and an effective amount of a compound of formula I
- 16. The composition according to claim 15 having a formula I compound wherein Q is SO2.
- 17. The composition according to claim 16 having a formula I wherein R4 is H or CH3 and R5 and R7 are H.
- 18. The composition according to claim 17 having a formula I compound wherein R6 is an optionally substituted phenyl or heteroaryl group.
- 19. The composition according to claim 16 having a formula I compound selected from the group consisting of:
2-{(E)-1-[1-(phenylsulfonyl)-1H-pyrrol-3-yl]ethylidene}hydrazinecarboximidamide; 2-{(E)-1-[1-(4-methylphenylsulfonyl)-1H-pyrrol-3-yl]ethylidene}hydrazine-carboximidamide; 2-{(E)-1-[1-(2,4-dimethyl-1-(phenylsulfonyl)-1H-pyrrol-3-yl]ethylidene}hydrazine-carboximidamide; 2-{(E)-1-[1-(naphthylsulfonyl)-1H-pyrrol-3-yl]ethylidene}-1-hydrazine-carboximidamide; 2-{(E)-1-{1-(5-chloro-3-methyl-1-benzothiophen-2-yl)sulfonyl]-1H-pyrrol-3-yl}ethylidene)-1-hydrazinecarboximidamide; 2-((E)-1-{1-[(4-aminophenyl)sulfonyl]-1H-pyrrol-3-yl}ethylidene)-1-hydrazine-carboximidamide; 2-((E)-1-{1-[(2-amino-4-methyl-1,3-thiazol-5-yl)sulfonyl]-1H-pyrrol-3-yl}ethylidene)-1-hydrazinecarboximidamide; 2-[1-[(phenylsulfonyl)-1,5,6,7-tetrahydro-4H-indol-4-ylidene]-1-hydrazinecarboximidamide; 2-[1-(4-biphenylsulfonyl)-1,5,6,7-tetrahydro-4H-indol-4-ylidene]-1-hydrazinecarboximidamide; 2-[1-(4-bromophenylsulfonyl)-1,5,6,7-tetrahydro-4H-indol-4-ylidene]-1-hydrazinecarboximidamide; 2-[1-(5-chloro-2-methoxyphenylsulfonyl)-1,5,6,7-tetrahydro-4H-indol-4-ylidene]-1-hydrazinecarboximidamide; the stereoisomers thereof; and the pharmaceutically acceptable salts thereof.
- 20. A process for the preparation of a compound of formula I
Parent Case Info
[0001] This application claims priority from co-pending application serial No. 60/357,032, filed on Feb. 14, 2002, the entire disclosure of which is hereby incorporated by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60357032 |
Feb 2002 |
US |